Clearside Biomedical
CLSD
CLSD was delisted on the 28th of November, 2025.
59 hedge funds and large institutions have $95.2M invested in Clearside Biomedical in 2017 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 21 increasing their positions, 9 reducing their positions, and 14 closing their positions.
133% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 9
7% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 14
0.06% less ownership
Funds ownership: 3.22% → 3.16% (-0.06%)
5% less funds holding
Funds holding: 62 → 59 (-3)
10% less capital invested
Capital invested by funds: $106M → $95.2M (-$10.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$6.29M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$4.1M |
| 3 |
HIM
Hillhouse Investment Management
Grand Cayman,
Cayman Islands
|
+$2.01M |
| 4 |
First Manhattan
New York
|
+$1.97M |
| 5 |
AIC
AWM Investment Company
New York
|
+$1.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
-$4.02M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$3.09M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$2.41M |
| 4 |
Millennium Management
New York
|
-$2.13M |
| 5 |
LCM
Laurion Capital Management
New York
|
-$1.83M |
CLSD Hedge Fund Activity: Q1 2017 in Review
59 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Clearside Biomedical (CLSD) for Q1 2017, worth a combined $95.2M — down 10% from $106M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new CLSD positions and 14 closed out — a net gain of 1 holder — while 21 added to existing stakes and 9 trimmed.
The largest buyer was BlackRock, adding an estimated $6.29M. The largest seller was Marshall Wace, exiting entirely with an estimated $4.02M sold.
- 59 institutional investors held Clearside Biomedical (CLSD) as of Q1 2017, down from 62 in Q4 2016.
- Funds reported $95.2M of Clearside Biomedical stock for Q1 2017, down 10% quarter-over-quarter.
- 15 funds opened new Clearside Biomedical positions in Q1 2017 and 14 closed out, a net change of +1 holder.
- The largest Clearside Biomedical buyer in Q1 2017 was BlackRock, an estimated $6.29M added.
- The largest Clearside Biomedical seller in Q1 2017 was Marshall Wace, an estimated $4.02M sold.
Based on aggregated 13F filings for Q1 2017.